Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months
| Group | Value (mm) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -0.32 | 0.693 |
| SMC021 Placebo | -0.40 | 0.768 |
Trial · Interventional
TerminatedPhase 3Results postedRegistry dataThis trial was stopped early.
Reason given at the registry: Male subjects were terminated due to an imbalance in prostate cancer events
Results were posted for this trial.
United States, Belgium, Canada, Czechia, Denmark, Hong Kong, Poland, Romania, Spain, United Kingdom
1 trial · 1 stopped early · 1 with posted results
Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)
NCT00704847Jun 2008 to Jun 2011
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee
Active comparator
1
SMC021 Oral Calcitonin
Placebo comparator
2
SMC021 Placebo
Outcomes the sponsor listed as primary.
Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months
Time frame · Change from baseline to 24 months
The signal knee was chosen prior to randomization based on which knee met the inclusion and exclusion criteria. The JSW is the space measured in mm between the 2 bones in the knee joint and this is assessed by x-ray. The JSW decreases with disease progression. The lower limit for participation in the trial were 2 mm JSW. There were no upper limit as long as inclusion and exclusion criteria were met. The outcome was measured as a change in JSW from baseline to month 24.
Pain Subscore Change From Baseline Over 24 Months as Assessed by Western Ontario and McMaster Universities Arthritis (WOMAC) Index
Time frame · Change from baseline to 24 months
WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the pain associated with performing each daily activity listed in the questionnaire. 0 is no pain (best), 100 is extreme pain (Worst). The total pain sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 500. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less pain).
Bone & Cartilage Metabolism Biochemical Marker Change (Percentage).
Time frame · From baseline to 24 months
The central laboratory analyzed serum CTX-I (S-Crosslaps, Elecsys) and osteocalcin as well as urine CTX I/creatinine and CTX-II/creatinine. These biomarkers were analysed in order to assess the cartilage and bone turonver ratio to baseline at month 24.
Knee Disease Progression Assessed by MRI
Time frame · From baseline to month 12 and month 24
Knee cartilage volume and thickness was assessed by MRI in patients from the sites in Ballerup, Denmark, the Czech Republic, and Romania using a quality controlled low-field 0.18T C-Span scanner from Esaote dedicated to the imaging of extremities. The same solenoid coil was used for all patients at a given site.
Questionnaire to Assess Function and Physical Activity
Time frame · From baseline to months 1, 6, 12 and 24
Function and physical activity were assessed by assessed by WOMAC function sub-score in the signal knee. The criteria for assessment of the functional classification according to the American Rheumatism Association (ARA) were as follows (Hochberg et al 1992): I. Completely able to perform usual activities of daily living (self-care, vocational and avocational) II. Able to perform usual self-care and vocational activities, but limited in avocational activities. III. Able to perform usual self-care activities, but limited in vocational and avocational activities. IV. Limited ability to perform usual self-care activities, vocational and avocational activities. Self-care activities included dressing, feeding, bathing, grooming, and toileting. Avocational (recreational and/or leisure) and vocational (work, school, homemaking) activities were patient-desired and age- and sex-specific.
Questionnaire to Assess Stiffness in the Signal Knee.
Time frame · Baseline to month 24
WOMAC's stiffness subscore was used to assess the stiffness in the signal knee. WOMAC is a self-administered set of standardized questionnaires to evaluate the condition of patients with osteoarthritis of the knee. The subject marks on a scale (1-100) the degree of joint stiffness for when performing each daily function listed in the questionnaire. 0 is no stiffness (best), 100 is extreme stiffness (worst). The total function sub score for the questions are then calculated. Total possible minimum sub score is 0, maximum is 200. The final outcome is the absolute change from baseline to 24 months. If the outcome is less that 0 there is improvement (less stiffness). Patients were instructed not to take analgesics for 3 days prior to the WOMAC test.
Questionnaire to Assess Health-related Quality of Life
Time frame · From baseline to month 24
Health-related quality of life was assessed by the EQ-5D questionnaire, which is a patient questionnaire for measure of health, developed by the EuroQol Group.The EQ-5D questionnaire was administered to patients in order to measure change in health-related quality of life (HRQoL) over 2 years. The subjects marks on a VAS scale from 0 to 100 the number that best describes their health today (0 is worst imaginable health state and 100 is best imaginable health state). The change from baseline in the EQ-5D VAS was calculated.
Questionnaire to Assess Pain
Time frame · Baseline, month 1, month 6, month 12, month 24
Pain was assessed by the WOMAC subscore in the signal knee by visit. Patients assessed their current pain level using a 100 mm visual analogue scales (VAS) by placing an X on the line that best describes his/her pain, where 0 equaled "No Pain" and 100 equaled "Worst Pain Imaginable". Patients were instructed not to take analgesics for 3 days prior to the VAS.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
| Group | Value (mm) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -0.32 | 0.693 |
| SMC021 Placebo | -0.40 | 0.768 |
| Group | Value (Units on a scale) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -80.6 | 112.22 |
| SMC021 Placebo | -87.9 | 116.25 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | 50.6 | 83.74 |
| SMC021 Placebo | 40.6 | 45.52 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | 3.4 | 9.11 |
| SMC021 Placebo | 3.0 | 13.16 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -4.8 | 44.89 |
| SMC021 Placebo | -1.9 | 131.20 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -26.1 | 90.88 |
| SMC021 Placebo | -20.3 | 179.22 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | 13.70 | 38.763 |
| SMC021 Placebo | 11.82 | 40.645 |
| Group | Value (percentage of change) | Spread |
|---|---|---|
| SMC021 Oral Calcitonin | -6.7 | 49.50 |
| SMC021 Placebo | -9.1 | 45.26 |
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| SMC021 Oral Calcitonin0.8 mg SMC021 Oral Calcitonin twice daily | – | 77 / 520 | 474 / 520 |
| SMC021 Placebo1 SMC021 Placebo tablet twice daily | – | 80 / 508 | 459 / 508 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
1 study on this page
Indexing hint: Randomized controlled trial · 2015
Karsdal et al. 2015Osteoarthritis and cartilagecited by 109
PMID 25582279DOI 10.1016/j.joca.2014.12.019PUB-25582279
1 study on this page
PubMed tag: none · 2026
Bay-Jensen et al. 2026BMC rheumatology
PMID 41764561PMC13059256DOI 10.1186/s41927-026-00628-wPUB-41764561
References listed at the registry that are not in PepBank. They link to PubMed.
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated